3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
5
Lymphoma, Non-Hodgkin
5
Hodgkin Disease
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Neoplasms
2
Multiple Myeloma
2
Pancreatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts